Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.
Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.
Status check updated to Retatrutide in Kenya. Not approved or available for public use; verify Kenya product and facility claims.
Lilly states that retatrutide has not been approved by any regulatory agency, is not available for public use, and is legally available only through Lilly-sponsored clinical trials. A Kenya listing cannot inherit that clinical identity. The Pharmacy and Poisons Board product register and facilities licence register answer separate questions about an exact product and the entity offering it. Both records must match before interpreting a local offer.
This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status.
A Kenya guide to checking peptide-related product claims in the Pharmacy and Poisons Board product register and matching the responsible retail, wholesale, hospital, or manufacturing facility in the public licence register.
This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.
Each selection has a shareable URL, so you can send someone the exact peptide and destination without losing the identity or country context.
The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.
No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.
The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.
No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.
Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.
Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.
Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.